Inotiv Leverages LifeNet Health Proprietary Platform to Advance New Approach Methodologies in Translational Drug Discovery
Rhea-AI Summary
Inotiv (NASDAQ: NOTV) announced on January 13, 2026 a strategic initiative to integrate LifeNet Health’s patented TruVivo® platform into its Discovery and Translational Sciences (DTS) business.
The TruVivo® system uses primary human hepatocytes with human-derived feeder cells to build physiologically relevant in vitro models intended to improve translational predictivity. Inotiv said the integration will align preclinical models more closely with human biology and enable expansion of human-relevant tissue models beyond the liver to support clients across a range of diseases.
The companies framed the collaboration as advancing new approach methodologies to accelerate development of safer, more effective therapies.
Positive
- None.
Negative
- None.
News Market Reaction
On the day this news was published, NOTV declined 3.25%, reflecting a moderate negative market reaction. Argus tracked a trough of -4.6% from its starting point during tracking. Our momentum scanner triggered 4 alerts that day, indicating moderate trading interest and price volatility. This price movement removed approximately $714K from the company's valuation, bringing the market cap to $21M at that time.
Data tracked by StockTitan Argus on the day of publication.
Market Reality Check
Peers on Argus
NOTV was up 1.78% pre-news, while peers showed mixed moves: BDSX up 15.51%, PRPO up 5.98%, ADVB up 5.42%, PRPH down 15.91%, and ISPC roughly flat. Momentum scanner also flagged ISPC down 5.30% and MYNZ up 5.07%, supporting a stock-specific rather than sector-wide pattern.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Dec 11 | AI partnership | Positive | -4.5% | AI/ML bioinformatics collaboration to enhance drug discovery capabilities. |
| Dec 03 | Earnings update | Positive | +8.1% | Q4 and FY2025 results with revenue growth and narrowed operating loss. |
| Nov 25 | Growth ranking | Positive | +3.9% | Deloitte Fast 500 ranking highlighting multi-year revenue growth. |
| Nov 21 | Earnings date notice | Neutral | -3.9% | Announcement of timing for Q4/FY2025 earnings release and call. |
| Nov 17 | Prelim results | Positive | -33.2% | Preliminary FY2025 revenue and strong DSA growth ahead of audit. |
Recent news with operational or partnership positives has produced mixed reactions, with both strong rallies and sharp selloffs around fundamentally constructive updates.
Over the last few months, Inotiv reported preliminary Q4/FY2025 results with strong Discovery and Safety Assessment growth but saw a -33.2% move following that update. Subsequent formal earnings on Dec 3, 2025 with revenue of $513.0M and improved operating loss coincided with an 8.13% gain. Recognition in the 2025 Deloitte Technology Fast 500™ produced a modest positive reaction, while an AI-focused VUGENE partnership drew a -4.48% move. Today’s translational science collaboration fits this pattern of strategic initiatives alongside volatile market responses.
Regulatory & Risk Context
An active S-3 shelf dated 2025-08-29 permits future securities offerings, including an at-the-market program with up to 3.0% commission under a Jefferies sales agreement. The filing includes an auditor’s going concern warning, notes material weaknesses in internal control over financial reporting, and highlights potential immediate dilution and variability of proceeds for investors.
Market Pulse Summary
This announcement expands Inotiv’s Discovery and Translational Sciences offering by integrating LifeNet Health’s TruVivo® platform, aiming to improve human-relevant, in vitro liver and tissue models. It follows recent growth in DSA services and strategic AI collaborations. Investors may weigh this innovation against regulatory disclosures, including an S-3 shelf with going concern language and dilution risk, and should watch how future earnings and DSA backlog trends reflect adoption.
Key Terms
hepatocytes medical
in vitro medical
preclinical medical
translational science medical
AI-generated analysis. Not financial advice.
WEST LAFAYETTE, Ind., Jan. 13, 2026 (GLOBE NEWSWIRE) -- Inotiv, Inc. (NASDAQ: NOTV) (the “Company”, or “Inotiv”), a leading Contract Research Organization specializing in nonclinical and analytical drug discovery and development services and research models and related products and services, today announced a strategic initiative to leverage LifeNet Health’s proprietary TruVivo® within its Discovery and Translational Sciences business.
LifeNet Health, a global leader in regenerative medicine, has developed the patented TruVivo® system, which uses primary human hepatocytes cultured with human-derived feeder cells to create physiologically relevant in vitro models. This technology provides a stronger foundation for predicting human responses to new therapies and addresses a critical challenge in drug development.
“Translational science is about connecting basic research to patient outcomes,” said Scott Daniels, PhD, Senior Vice President of Discovery & Translational Sciences (DTS) at Inotiv. “Integrating the TruVivo® platform into our disease pharmacology offering allows us to better align preclinical models with human biology. The versatility of LifeNet Health’s platform will also enable us to extend human-relevant tissue models beyond the liver, advancing innovation for clients addressing a wide range of human diseases.”
“Our mission is to Save Lives, Restore Health and Give Hope by accelerating scientific innovation that translates into meaningful human impact,” said Susan Campbell, General Manager LifeSciences at LifeNet Health, “and this collaboration underscores our shared vision of transforming preclinical research through human-relevant technologies.”
By leveraging LifeNet Health’s proprietary platform, Inotiv strengthens its commitment to new approach methodologies that advance human-relevant science, improve translational predictivity, and accelerate the development of safer, more effective therapies for patients.
About Inotiv
Inotiv, Inc. is a leading contract research organization dedicated to providing nonclinical and analytical drug discovery and development services and research models and related products and services. The Company’s products and services focus on bringing new drugs and medical devices through the discovery and preclinical phases of development, all while increasing efficiency, improving data, and reducing the cost of taking new drugs and medical devices to market. Inotiv is committed to supporting discovery and development objectives as well as helping researchers realize the full potential of their critical research and development projects, all while working together to build a healthier and safer world. Further information about Inotiv can be found here: https://www.inotiv.com/.
About LifeNet Health LifeSciences
LifeNet Health LifeSciences delivers human-based research solutions that accelerate discovery and improve patient safety. As part of LifeNet Health, a nonprofit organization dedicated for over 40 years to saving lives, we bridge donation and science with unmatched human relevance. Our portfolio includes characterized liver cells and tissues, prospective biospecimen recovery, and advanced in vitro systems, empowering researchers worldwide to develop safer, more effective therapies. To learn more, visit: https://lnhlifesciences.org.
This release contains "forward-looking statements," within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are generally identified with words such as “aim”, “anticipate”, “assume”, “believe”, “could”, “estimate”, “expect”, “future”, “goal”, “intend”, “likely”, “may”, “plan”, “project”, “seek”, “strategy”, “target”, “will” and similar expressions. Forward-looking statements in this release include, but are not limited to, statements regarding the Company’s new strategic collaboration, including the workings of the collaboration and its expected effects, impacts and results, potential expansions and additional innovation, and commitments to new approach methodologies and their expected effects, impacts and results. These forward-looking statements are not statements of historical facts and represent only the Company’s current expectations regarding such matters. All forward-looking statements are subject to significant risks, uncertainties and changes in circumstances that could cause actual results and outcomes to differ materially from those expressed or implied in the forward-looking statements, including, but are not limited to, those detailed in the Company's filings with the U.S. Securities and Exchange Commission. Further discussion of these risks, uncertainties, and other matters can be found in the Risk Factors detailed in the Company’s Annual Report on Form 10-K as filed on December 5, 2025, as well as other filings with the Securities and Exchange Commission. Except to the extent required by law, the Company does not undertake, and expressly disclaims, any duty or obligation to update publicly any forward-looking statement after the date of this release, whether as a result of new information, future events, changes in assumptions or otherwise.
| Inotiv Company Contact | Inotiv Investor Relations | |
| Inotiv, Inc. | LifeSci Advisors | |
| Beth A. Taylor, Chief Financial Officer | Steve Halper | |
| (765) 497-8381 | (646) 876-6455 | |
| beth.taylor@inotiv.com | shalper@lifesciadvisors.com | |
| LifeNet Health Media Contact | ||
| stratcomm@lifenethealth.org |
FAQ
What did Inotiv (NOTV) announce on January 13, 2026 about LifeNet Health?
How does the TruVivo® platform used by NOTV work and what models does it target?
What is the stated goal of Inotiv’s integration of LifeNet Health technology?
Which Inotiv business unit will leverage LifeNet Health’s TruVivo® system?
Will the TruVivo® integration expand beyond liver models according to Inotiv (NOTV)?
Does the announcement include financial guidance or transaction terms for NOTV?
